Hyperlipidemia and primary prevention of stroke: Does risk factor identification and reduction really work

Current Atherosclerosis Reports

Volumn 12, Issue 4, 2010, Pages 225-229

  Lewis, Ariane ^a   Segal, Alan ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Cholesterol; HDL; Hyperlipidemia; LDL; Statins; Stroke

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ARTERY OCCLUSION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIETARY INTAKE; DRUG DOSE COMPARISON; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; LIPID ANALYSIS; MYOPATHY; NONHUMAN; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRIMARY PREVENTION; REVIEW; RISK FACTOR; RISK REDUCTION; ARTICLE; FEMALE; MALE; MASS SCREENING; STROKE;

FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MASS SCREENING; RISK FACTORS; RISK REDUCTION BEHAVIOR; STROKE;

EID: 77955948228     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0117-4     Document Type: Review

References (27)

1. Lloyd-Jones D, Adams R, Brown T, et al.: Heart Disease and Stroke Statistics 2010 Update. A Report From the American Heart Association. Circulation 2010, 121:e1-e170. This article includes a thorough summary of the most up-to-date statistics on heart disease and stroke.
2. Castilla-Guerra L, Fernandez-Moreno M, Alvarez-Suero J: Secondary stroke prevention in the elderly: New evidence in hypertension and hyperlipidemia. Eur J Intern Med 2009, 20:586-590.
3. Agency for Healthcare Research and Quality: Screening for Lipid Disorders in Adults. Available at http://www.ahrq.gov/ CLINIC/uspstf/uspschol.htm. Accessed January 2010.
4. National Institutes of Health: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Available at http:// www.nhlbi.nih.gov/guidelines/cholesterol/atp-iii.htm. Accessed January 2010.
5. Goldstein LB: Statins and ischemic stroke severity: Cytoprotection. Curr Atheroscler Rep 2009, 11:296-300.
6. Rodriguez-Yanez M, Agulla J, Rodriguez-Gonzalez R, et al.: Statins and stroke. Ther Adv Cardiovasc Dis 2008, 2:157-166.
7. Jones P, Kafonek S, Laurora I, et al.: Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients with Hypercholesterolemia (The CURVES Study). Am J Cardiol 1998; 81:582-587.
8. Crouse JR, Frohlich J, Ose L, et al.: Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-1. Am J Cardiol 1999, 83:1476-1477.
9. Foody JM, Joyce A, Rudolph A, et al.: Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: A large database analysis of managed care plans in the united states. Clin Ther 2008; 30:195-205.
10. Horimoto Y, Matsubara M, Mizutani H, et al.: Effects of pitavastatin on cerebral blood flow. Clin Ther 2009, 31:575-579.
11. Tan T, Kuo YL, Lin WC, et al.: Effect of lipid-lowering therapy on progression of intracranial arterial stenosis. J Neurol 2009, 256:187-193.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) [no authors listed]. Lancet 1994, 344:1383-139.
13. Amarenco P, Labreuche J: Lipid management in the prevention of stroke: Review and updated meta-analysis of statins for stroke prevention. Lancet 2009,8:453-463. This meta-analysis summarizes the results of 24 studies on the impact of lipid control on strokes.
14. Gardener H, Della Morte D, Elkind M, et al.: Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). BMC Cardiovasc Disord 2009, 9:55.
15. Asplund K, Karvanen J, Giampaoli S, et al.: Relative risks for stroke by age, sex, and population based on follow-up of 18 European populations in the MORGAM Project. Stroke 2009, 40:2319-2326.
16. Pilote L, Dasgupta K, Guru V, et al.: A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007, 176:S1-S44.
17. Yu AY, Keezer MR, Zhu B, et al.: Pre-stroke use of antihypertensives, antiplatelets, or statins and early ischemic stroke outcomes. Cerebrovasc Dis 2009, 27:398-402.
18. Fuentes B, Martinez-Sanchez P, Diez-Tejedor E: Lipid-lowering drugs in ischemic stroke prevention and their influence on acute stroke outcome. Cerebrovasc Dis 2009, 27(Suppl 1):126-133.
19. Prinz V, Endres M: The acute (cerebro)vascular effects of statins. Anesth Analg 2009; 109:572-584.
20. Goldstein L, Amarenco P, Zivin J, et al.: Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009, 40:3526-3531.
21. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. N Engl J Med 2005, 352:1425-1435.
22. Ridker P: Moving toward new statin guidelines in a Post- JUPITER World: Principles to consider. Curr Atherscler Rep 2009, 11:249-256.
23. John S, Schneider M, Delles C, et al.: Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005, 149:473.e1-e10.
24. Nolte CH, Jungehulsing J, Rossnagel K, et al.: Vascular risk factor awareness before and pharmacological treatment before and after stroke and TIA. Eur J Neurol 2009, 16:678-683.
25. Lewis SJ, Robinson JG, Fox KM, et al.: Underutilisation of cardiovascular medications among at-risk individuals. Int J Clin Pract 2009 (in press).
26. Romero JR, Morris J, Pikula A: Stroke prevention: Modifying risk factors. Ther Adv Cardiovasc Dis 2008, 2:287-303. This review article addresses stroke risk factors and primary and secondary prevention.
27. Labarthe D, Dai S, Day R, et al.: Findings from Project HeartBeat! Their importance for CVD prevention. Am J Prev Med 2009, 37(Suppl 1):S105-115.